Pharmaceutical industry
MorphoSys AG, a biotechnology company based in Germany, has announced a new five-year alliance with ContraFect Corp., a US-based biotech company, to collaborate on the discovery and development of therapeutic antibodies for infectious diseases. The agreement will provide ContraFect with access to MorphoSys's HuCAL PLATINUM technology and AutoCAL
Pharmaceutical industry
The NASDAQ stock market showed significant movement in the after-hours trading session, with both notable gainers and losers. Expedia Inc., Seagate Technology, Cutera, ShoreTel, and Select Comfort took the top spots as gainers, while Hercules Offshore, Idenix Pharmaceuticals, Sangamo Biosciences, PostRock Energy, and China-Biotics led the pack as losers. Key
Pharmaceutical industry
The NASDAQ Stock Market's pre-market trading shows significant gains and losses among top stocks. Conns Inc. (CONN) leads the gainers with a 31.83% increase, while Hercules Offshore (HERO) leads the losers with a 9.25% decline. Expedia Inc. (EXPE) is expected to undergo a spin-off into two
Pharmaceutical industry
At the upcoming 102nd Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, ImmunoGen scientists will present nine study abstracts, including eight posters and one oral presentation, showcasing the company's Targeted Antibody Payload (TAP) technology and its applications in cancer treatment. The presentations highlight
Pharmaceutical industry
Seattle Genetics, Inc. (Nasdaq: SGEN) and Millennium: The Takeda Oncology Company have expanded their existing antibody-drug conjugate (ADC) collaboration, with Millennium exercising an option to designate a second antigen target for the development of ADCs. This move demonstrates Millennium's commitment to Seattle Genetics' ADC technology, which has
Pharmaceutical industry
Aurora A kinase is an essential therapeutic target in cancer treatment, according to a study published in Cancer Research. Researchers from Millennium Pharmaceuticals, Inc. evaluated the effectiveness of MLN8054, a small-molecule inhibitor of Aurora A kinase, in patients with advanced solid tumors. The study revealed promising results, with several patients
Pharmaceutical industry
InNexus Biotechnology Inc. (TSX:IXS.V), a leading drug development company, has reported on its accomplishments and progress during 2010, as well as its outlook for 2011. The company has refocused its efforts on three distinct healthcare markets: ophthalmology, dermatology, and oncology, with multiple candidates in each opportunity. InNexus has
Pharmaceutical industry
BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing products for female sexual health and oncology, will present at the 13th Annual CEO & Investor Conference hosted by the Biotechnology Industry Organization (BIO). Stephen M. Simes, BioSante's president & CEO, will provide an overview of the company
Pharmaceutical industry
Oncolytics Biotech Inc. has begun enrollment in a 2-Arm randomized Phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first-line treatment of patients with recurrent or metastatic pancreatic cancer. The trial is sponsored by the U.S. National Cancer Institute and is an open-label,
Pharmaceutical industry
Curetech Ltd. has reached a significant milestone in its drug development pipeline by completing the recruitment phase for its Phase II clinical trial of the monoclonal antibody CT-011 for treating metastatic colorectal cancer. The trial, which will involve 171 patients undergoing chemotherapy, is expected to last 18 months, with final
Pharmaceutical industry
Oncolytics Biotech Inc has announced that enrollment has begun in a Phase II study of its oncolytic virus Reolysin in combination with standard chemotherapy carboplatin and paclitaxel for the treatment of patients with recurrent or metastatic pancreatic cancer. The study aims to assess the efficacy of Reolysin in improving progression-free
Pharmaceutical industry
Kamada Ltd., an Israeli pharmaceutical company, is set to commence a Phase I/II clinical trial in Israel for its intravenous Alpha-1 Antitrypsin (AAT) gene replacement therapy to treat type 1 diabetes. This comes on the heels of the US FDA's approval of the same drug, Glassia, for
